Added to YB: 2026-10-08
Pitch date: 2026-10-04
QTTB [bullish]
Q32 Bio Inc.
-3.96%
current return
Author Info
No bio for this author
Company Info
Q32 Bio Inc., a clinical-stage biotechnology company, develops novel biologics to restore healthy immune balance in patients with alopecia areata and other autoimmune and inflammatory diseases driven by pathological immune dysfunction.
Market Cap
$249.2M
Pitch Price
$8.09
Price Target
N/A
Dividend
N/A
EV/EBITDA
6.31
P/E
3.68
EV/Sales
2.76
Sector
Biotechnology
Category
growth
Free under $10 Ticker Biotech Quarter Review Tier 1 basket — strategic biotech and specialty pharma - Q32 Bio Inc.
QTTB (update): Q32 Bio’s case now centers on bempikibart for severe alopecia areata: Phase 2a produced a 35.3% mean SALT-score reduction at Week 36, while all 12 responders maintained response off drug and 42% deepened it. A registration-directed program is planned for 1H27, and durable, lower-frequency maintenance could attract dermatology buyers, but the small open-label dataset is not registrational proof.
Read full article (1 min)